ATE359509T1 - Ersatz für zielobjekte und verbesserten referenzplatten - Google Patents

Ersatz für zielobjekte und verbesserten referenzplatten

Info

Publication number
ATE359509T1
ATE359509T1 AT02009879T AT02009879T ATE359509T1 AT E359509 T1 ATE359509 T1 AT E359509T1 AT 02009879 T AT02009879 T AT 02009879T AT 02009879 T AT02009879 T AT 02009879T AT E359509 T1 ATE359509 T1 AT E359509T1
Authority
AT
Austria
Prior art keywords
reactivity
receptor
panel
panels
members
Prior art date
Application number
AT02009879T
Other languages
English (en)
Inventor
Lawrence M Kauvar
Hugo O Villar
Original Assignee
Telik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/177,673 external-priority patent/US5587293A/en
Application filed by Telik Inc filed Critical Telik Inc
Application granted granted Critical
Publication of ATE359509T1 publication Critical patent/ATE359509T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Laminated Bodies (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Control Of Driving Devices And Active Controlling Of Vehicle (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Forklifts And Lifting Vehicles (AREA)
  • Stabilization Of Oscillater, Synchronisation, Frequency Synthesizers (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
AT02009879T 1994-01-06 1995-01-05 Ersatz für zielobjekte und verbesserten referenzplatten ATE359509T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/177,673 US5587293A (en) 1994-01-06 1994-01-06 Method to identify binding partners
US08/308,813 US5798275A (en) 1994-01-06 1994-09-19 Profiling reference panel enriched by non-IG proteins

Publications (1)

Publication Number Publication Date
ATE359509T1 true ATE359509T1 (de) 2007-05-15

Family

ID=26873529

Family Applications (2)

Application Number Title Priority Date Filing Date
AT95906754T ATE236401T1 (de) 1994-01-06 1995-01-05 Surrogate für bindemoleküle und verbesserte referenzpanele
AT02009879T ATE359509T1 (de) 1994-01-06 1995-01-05 Ersatz für zielobjekte und verbesserten referenzplatten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT95906754T ATE236401T1 (de) 1994-01-06 1995-01-05 Surrogate für bindemoleküle und verbesserte referenzpanele

Country Status (11)

Country Link
US (1) US5741653A (de)
EP (1) EP0738390B1 (de)
JP (1) JPH09507300A (de)
AT (2) ATE236401T1 (de)
AU (1) AU700497B2 (de)
CA (1) CA2178096C (de)
DE (2) DE69530179T2 (de)
DK (2) DK1235072T3 (de)
ES (2) ES2284743T3 (de)
PT (1) PT738390E (de)
WO (1) WO1995018969A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6805861B2 (en) 1996-01-17 2004-10-19 Imperial College Innovations Limited Immunotherapy using cytotoxic T lymphocytes (CTL)
US6054286A (en) * 1996-06-18 2000-04-25 Telik, Inc. Methods to identify immunomodulators using cognate interaction of PKC-theta
AU5902098A (en) * 1997-01-03 1998-07-31 Terrapin Technologies, Inc. Method to classify gene products
CA2238283C (en) * 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
HU225767B1 (en) 1997-11-12 2007-08-28 Dimensional Pharmaceuticals 3 High throughput method for functionally classifying proteins identified using a genomics approach
EP1049796A1 (de) * 1997-12-18 2000-11-08 Sepracor, Inc. Verfahren für die gleichzeitige identifizierung von neuen biologischen zielen und "leadersequenzen" für die medikamentenentwicklung
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
IL141107A0 (en) * 1998-08-05 2002-02-10 Univ Pittsburgh A method for determining the tendency for metabolism of a compound by an enzyme
US6625547B1 (en) 1998-08-05 2003-09-23 Washington State University Research Foundation Relative rates of cytochrome p450 metabolism
CA2339817A1 (en) * 1998-08-12 2000-02-24 Zycos Inc. Profiling and cataloging expressed protein tags
US20040224338A1 (en) * 1998-08-12 2004-11-11 Zycos Inc., A Delaware Corporation Profiling and cataloging expressed protein tags
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6569631B1 (en) 1998-11-12 2003-05-27 3-Dimensional Pharmaceuticals, Inc. Microplate thermal shift assay for ligand development using 5-(4″dimethylaminophenyl)-2-(4′-phenyl)oxazole derivative fluorescent dyes
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6875575B1 (en) 1998-11-25 2005-04-05 Osi Pharmaceuticals, Inc. Diagnostic methods for neoplasia
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
EP3712897A1 (de) * 2019-03-22 2020-09-23 Tata Consultancy Services Limited Automatisierte vorhersage der biologischen reaktion von chemischen verbindungen auf der basis chemischer informationen

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5133866A (en) * 1988-03-24 1992-07-28 Terrapin Technologies, Inc. Method to identify analyte-bending ligands
US5300425A (en) * 1987-10-13 1994-04-05 Terrapin Technologies, Inc. Method to produce immunodiagnostic reagents
US4963263A (en) * 1988-03-24 1990-10-16 Terrapin Technologies, Inc. Method of identity analyte-binding peptides
US5217869A (en) * 1987-10-13 1993-06-08 Terrapin Technologies, Inc. Method to produce immunodiagnostic reagents
US5338659A (en) * 1991-04-02 1994-08-16 Terrapin Technologies, Inc. Method for determining analyte concentration by cross-reactivity profiling
EP0387276B1 (de) * 1987-10-13 1997-04-23 Terrapin Technologies, Inc. Verfahren zur herstellung von imunodiagnose-mitteln
US5340474A (en) * 1988-03-24 1994-08-23 Terrapin Technologies, Inc. Panels of analyte-binding ligands
HUT65361A (en) * 1989-12-29 1994-05-02 Univ Technologies Int Method for modelling tertiary structures of biologically active ligands including agonists and antagonists thereto and novel synthetic antagonists based on angiotensin
JPH06502723A (ja) * 1990-11-09 1994-03-24 ヴェリジェン，インコーポレーテッド 抗体を検出する分析系の感度及び／又は特異性の決定方法

Also Published As

Publication number Publication date
DK1235072T3 (da) 2007-07-16
PT738390E (pt) 2003-07-31
ES2196056T3 (es) 2003-12-16
DE69535463D1 (de) 2007-05-24
AU1522195A (en) 1995-08-01
CA2178096C (en) 2004-03-09
CA2178096A1 (en) 1995-07-13
EP0738390B1 (de) 2003-04-02
EP0738390A1 (de) 1996-10-23
DE69530179D1 (de) 2003-05-08
US5741653A (en) 1998-04-21
DE69530179T2 (de) 2004-04-08
DE69535463T2 (de) 2008-01-03
AU700497B2 (en) 1999-01-07
ES2284743T3 (es) 2007-11-16
DK0738390T3 (da) 2003-07-21
JPH09507300A (ja) 1997-07-22
ATE236401T1 (de) 2003-04-15
WO1995018969A1 (en) 1995-07-13

Similar Documents

Publication Publication Date Title
DE69535463D1 (de) Ersatz für Zielobjekte und verbesserten Referenzplatten
DK0933082T3 (da) Fremgangsmåde til manipulation af celledifferentiering
DK0749325T3 (da) Bispecifikke molekyler med klinisk anvendelse
BR9808545A (pt) ácido nucleico isolado, vetor de expressão, célula hospedeira, processos para produzir uma proteìna de ligação da osteoprotegerina, para detectar a presença de uma proteìna de ligação à osteoprotegerina em uma amostra biológica, para avaliar a capacidade de um composto candidato de ligar-se a uma proteìna de ligação da osteoprotegerina e de um composto de teste para aumentar ou reduzir a ligação da proteìna de ligação da osteoprotegerina a odar, para regular a expressão de uma proteìna de ligação da osteoprotegerina em um animal e para prevenir ou tratar de doença óssea em um mamìfero, polipeptìdeo, protéina de ligação da osteroprotegerina purificada e isolada, ou seu fragmento, análogo ou derivado, e, anticorpo ou seu fragmento
DE69321218D1 (de) Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4
ATE315654T1 (de) Diagnose und behandlung von mit aur-1 und/oder aur-2 assoziierten erkrankungen
BR9106217A (pt) Processo para a analise de uma amostra de gas,disposicao de analise,empregos disto e instalacao de teste com a citada disposicao
BR9508417A (pt) Acido nucléico isolado cdna isolado proteina isolada vetor de expressão processo para detectar câncer e pré-câncer de pulmão processo para selecionar especimes humanas para proteina hcaviii processo para testar amostra de célula humana anticorpo e composição terapêutica
ATE461450T1 (de) Verwendung von kontrollflächen zur detektion von störproben in einem nachweisverfahren
ATE113962T1 (de) Von polypeptiden induzierte monoklonale antikörper gegen oncoproteine.
Righetti et al. The proteome: anno Domini 2002
DK1117685T3 (da) Behandling af inflammatorisk sygdom
Segura et al. Procedures for monitoring recombinant erythropoietin and analogues in doping control
ATE258310T1 (de) Testverfahren für collagenpeptid
BR9607854A (pt) Processos para a medição da taxa de degradação de uma proteína do corpo e para obtenção de informação referente à degradação de proteína em um paciente utilização de um isômero sintético de um peptídeo e de um anticorpo anticorpo capa de células análogo de peptídeo sintético e kit de análise para utilização em um processo de análise
ATE239274T1 (de) Proteom-analyse zum charakterisieren von auf- und abgeregelten proteinen in biologischen proben
ATE363070T1 (de) Auswertung von biologischen mitteln in lebenden zielzellen
DK26587D0 (da) Monoklonalt antistof, maalemetode for glucosyleret protein ved anvendelse af det monoklonale antistofog kit omfattende dette
ATE186553T1 (de) Competitives enzym-testverfahren zum nachweis von phosphothioaten
DK0789844T3 (da) Anvendelse af et BMP-proteinreceptor-kompleks til screening for aktive stoffer i knoglemetabolisme og celler, der er cotransficieret med en type II-BMP-receptor og en type I-BMP-receptor
SE0003566D0 (sv) A method for the quantitative determination of one or more compounds
Gooderham In situ peptide mapping of proteins following polyacrylamide gel electrophoresis
Williams Immunoelectrophoresis
DK162726C (da) Fremgangsmaade til eliminering af falsk positive resultater ved bestemmelse af atl virus-antistof og reagens dertil
Murthy Identification of false-positive CK-MB activity in an elderly patient

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1235072

Country of ref document: EP

REN Ceased due to non-payment of the annual fee